Airway Medix S.A. Confirms Execution of Its Strategic Direction
Airway Medix confirms the shift from a research and development company to an international trading company with its own products. The release describes the governance changes and the partnerships in Germany and Europe that support this direction.
Warsaw, May 5, 2026: Airway Medix S.A., a MedTech company listed on the Warsaw Stock Exchange, confirms that its current development is consistent with the path previously outlined in its public communication. The Company continues to implement its precisely planned development strategy, with a clear focus on transforming from a research-and-development-oriented business into a fully functioning international trading company.
Recent developments, including changes to the Company's governance structure and the ongoing strengthening of its international partnerships, are aligned with this direction. Airway Medix emphasizes that its activities are being executed within the framework of its existing, carefully structured development plan, without any shift in its fundamental approach.
The position of Airway Medix's German and other European partners is being intensified, both strategically and operationally. The Company continues to build upon an established, specialized German network with expertise in sales, distribution, regulatory navigation, and the commercialization of innovative MedTech devices. In this context, the Company highlights the continued active role of Peter Kröner, member of the Management Board and long-standing German partner, as well as the recent appointment of Dr. Matthias Kuss to the Supervisory Board.
"The combination of strong R&D, clear regulatory focus, and a structured, international sales and distribution network is essential for building a sustainable MedTech business," said Peter Kröner. "I am confident that the current developments are in line with the Company's long-term direction and that the team is well-positioned to execute its commercial plans with discipline and focus."
Dr. Kuss brings a forward-looking, experience-driven perspective, with a background spanning innovation management, corporate strategy, and international business development. His appointment reflects a governance approach that is open to new opportunities while remaining grounded in disciplined execution and risk-managed growth.
About Airway Medix S.A.: Airway Medix S.A. focuses on the research, development and commercialization of innovative disposable devices for mechanically ventilated patients in Intensive Care Units (ICUs), as well as life-threatening patients and anesthesiology departments. The products offered by Airway Medix address the most pressing clinical needs and fill a gap in current medical devices. Airway Medix S.A. has been listed on the Warsaw Stock Exchange since 2014.
Press releases are published as issued by Airway Medix S.A. Product statements follow the instructions for use.
